Skip to NavigationSkip to content

Ben Goldacre

Judge rules pharma has ‘ethical' transparency obligation – reaction

Scales of justice
Flickr/Mike Cogh

Both sides of a bitterly contested legal battle over a major part of the industry's transparency drive have reacted to the judge's verdict.

A judge ruled that the Health Research Authority is acting within the law in pushing through plans for companies to register clinical trials in active recruitment in the UK.

World Health Organisation calls for full trial transparency

WHO image
World Health Organization headquarters in Geneva

The World Health Organization has thrown its weight behind clinical trial transparency in a new statement on its position.

WHO says that researchers have an ‘ethical imperative’ to report results from clinical trials and that results should be made publicly available within 12 months of the study’s end – although it notes that it should be possible for reporting to occur in shorter timeframes in ‘most instances’.

Mixed response to EMA data transparency plans

EMA image
EMA headquarters

The European Medicines Agency has passed new rules that will mandate pharma to release more of its clinical trial data from the start of next year.

In what its executive director Guido Rasi describes as an ‘unprecedented’ step forward, the EMA has now decided to publish the clinical reports that underpin the decision-making on medicines.

Dr Ben Goldacre: “This is a very broken system”

Published on 19/10/10 at 08:00am
Andrew McConaghie
Dr Ben Goldacre

The pharma industry has its fair share of critics, but unfortunately for everybody, many are easy to dismiss - shrill, ill-informed campaigners who sometimes bear a grudge or border on being conspiracy theorists.

This is unfortunate because an industry as important as pharma needs articulate, rational, and reasoned criticism to keep it on its toes - and to bring about change when it is needed.

Researchers unearth Pfizer's buried data

Researchers from Germany’s cost-effectiveness body IQWiG have unearthed a mountain of unpublished data from trials of Pfizer’s reboxetine that show that the antidepressant may be harmful.

They found published studies overestimated reboxetine’s benefit by 115% when compared to placebo a

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches